Harrow (HROW) Aktienübersicht
Harrow, Inc. ist ein pharmazeutisches Unternehmen im Bereich der Augenheilkunde, das sich mit der Entdeckung, Entwicklung und Vermarktung von pharmazeutischen Produkten für die Augenheilkunde in den Vereinigten Staaten befasst. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 4/6 |
| Künftiges Wachstum | 5/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 2/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
Bei unseren Risikoprüfungen wurden keine Risiken für HROW festgestellt.
HROW Community Fair Values
Create NarrativeSee what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Harrow, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$40.44 |
| 52-Wochen-Hoch | US$54.85 |
| 52-Wochen-Tief | US$28.54 |
| Beta | 0.25 |
| 1 Monat Veränderung | -4.80% |
| 3 Monate Veränderung | 39.30% |
| 1 Jahr Veränderung | 19.86% |
| 3 Jahre Veränderung | 134.03% |
| 5 Jahre Veränderung | 359.02% |
| Veränderung seit IPO | 367.59% |
Aktuelle Nachrichten und Updates
Seeking Alpha • Jul 15
Harrow: Debt-Fueled Liquidity Masks An Operating Cash Problem
Summary Harrow remains a "Sell," as its growth is inorganic, margins are compressing, and ambitious revenue targets appear increasingly unrealistic. Q1 earnings revealed a $12.7 million adjusted EBITDA loss, gross margin contraction to 61%, and a 32.7% compounding revenue decline, highlighting operational challenges. Management reaffirmed 2026 guidance despite a significant Q1 revenue miss, requiring an aggressive second-half acceleration that leaves no margin for error. Heavy SG&A spend, GTN concessions, and reliance on debt-driven liquidity underscore fundamental flaws; mission-critical Q3/Q4 results will be pivotal for HROW’s credibility. Read the full article on Seeking AlphaAnalyseartikel • Jun 21
Harrow (HROW) Stock Could Be 37% Below Fair Value After VERKAZIA Relaunch
Harrow (HROW) is back in focus after the company re-launched VERKAZIA, a cyclosporine ophthalmic emulsion for vernal keratoconjunctivitis, supported by a broad push around physician education, patient access, and affordability. See our latest analysis for Harrow. Harrow’s recent VERKAZIA news has coincided with a sharp shift in sentiment, with the share price up 29.91% over 30 days and 26.09% over 90 days, yet still showing a year-to-date share price decline of 14.11%. At the same time,...
Narrative-Update • Jun 13
HROW: Future Upside Will Rely On Ophthalmic Volume And Catalyst Execution
Narrative Update on Harrow Harrow's updated analyst price target has shifted modestly lower, with the fair value estimate moving from $89.62 to $88.00 as analysts factor in weaker VEVYE pricing, revised growth expectations, and near term average selling price uncertainty alongside continuing volume strength and product momentum. Analyst Commentary Bullish analysts are trimming price targets but still framing Harrow as an execution story tied closely to product volumes and upcoming catalysts, rather than just near term pricing noise.Recent updates
Seeking Alpha • Jul 15
Harrow: Debt-Fueled Liquidity Masks An Operating Cash Problem
Summary Harrow remains a "Sell," as its growth is inorganic, margins are compressing, and ambitious revenue targets appear increasingly unrealistic. Q1 earnings revealed a $12.7 million adjusted EBITDA loss, gross margin contraction to 61%, and a 32.7% compounding revenue decline, highlighting operational challenges. Management reaffirmed 2026 guidance despite a significant Q1 revenue miss, requiring an aggressive second-half acceleration that leaves no margin for error. Heavy SG&A spend, GTN concessions, and reliance on debt-driven liquidity underscore fundamental flaws; mission-critical Q3/Q4 results will be pivotal for HROW’s credibility. Read the full article on Seeking AlphaAnalyseartikel • Jun 21
Harrow (HROW) Stock Could Be 37% Below Fair Value After VERKAZIA Relaunch
Harrow (HROW) is back in focus after the company re-launched VERKAZIA, a cyclosporine ophthalmic emulsion for vernal keratoconjunctivitis, supported by a broad push around physician education, patient access, and affordability. See our latest analysis for Harrow. Harrow’s recent VERKAZIA news has coincided with a sharp shift in sentiment, with the share price up 29.91% over 30 days and 26.09% over 90 days, yet still showing a year-to-date share price decline of 14.11%. At the same time,...Narrative-Update • Jun 13
HROW: Future Upside Will Rely On Ophthalmic Volume And Catalyst Execution
Narrative Update on Harrow Harrow's updated analyst price target has shifted modestly lower, with the fair value estimate moving from $89.62 to $88.00 as analysts factor in weaker VEVYE pricing, revised growth expectations, and near term average selling price uncertainty alongside continuing volume strength and product momentum. Analyst Commentary Bullish analysts are trimming price targets but still framing Harrow as an execution story tied closely to product volumes and upcoming catalysts, rather than just near term pricing noise.
Narrative-Update • May 29
HROW: Ophthalmic Portfolio And Trials Will Support Future Earnings Reacceleration
Narrative Update Analysts have trimmed Harrow's average price target slightly, with several firms lowering their targets into a roughly $60 to $88 range as they factor in revised expectations for VEVYE pricing, updated IHEEZO and VEVYE revenue assumptions, and refreshed company models following recent quarterly results. Analyst Commentary Recent research updates show a cluster of trimmed price targets for Harrow, generally landing in the US$60 to US$91 range, with most firms maintaining positive ratings but incorporating more conservative assumptions around revenue and pricing for key products.
Narrative-Update • May 14
HROW: Expanding Ophthalmic Portfolio And Coding Catalysts Will Drive Future Revenue Mix Diversification
Analysts have trimmed their average price target for Harrow by a few dollars, with cuts such as B. Riley moving to $60 from $65 and Cantor Fitzgerald moving to $88 from $91, as they factor in softer VEVYE pricing and moderated Iheezo and Vevye revenue, along with expectations for stronger product momentum and operating leverage over time.Narrative-Update • Apr 29
HROW: Ophthalmic Portfolio And Trials Will Support Long Term Earnings Reacceleration
The updated analyst price target for Harrow now sits at $59, reflecting a mix of modestly adjusted growth, margin and P/E assumptions as analysts recalibrate their models following Q4 results and revised product revenue guidance. Analyst Commentary Recent Street research on Harrow shows a cluster of price target revisions around the time of the Q4 report, with several bearish analysts trimming their models after updating revenue assumptions and aligning with management guidance.Narrative-Update • Apr 15
HROW: Future Upside Will Depend On Cataract Franchise Trial Execution
Harrow's updated analyst price target has edged lower by less than $1, reflecting analysts' refreshed revenue and margin assumptions following recent fourth quarter based model updates across the Street. Analyst Commentary Street research has recently focused on recalibrating price targets for Harrow after the latest fourth quarter update, with most firms fine-tuning models rather than changing their broader stance on the company.Narrative-Update • Apr 01
HROW: Ophthalmic Portfolio Expansion And Trials Will Support Long Term Earnings Power
Analysts have modestly reduced their average price targets on Harrow to a range of about $60 to $91, reflecting updated revenue estimates for products like Iheezo and Vevye and refreshed models following the latest Q4 report. Analyst Commentary Recent research indicates that while the overall stance on Harrow remains constructive, several Bearish analysts have trimmed their price targets and underlying revenue assumptions following the Q4 report.Narrative-Update • Mar 17
HROW: Ophthalmic Pipeline And New Trials Are Expected To Strengthen Long Term Earnings Power
Analysts have trimmed their consolidated Harrow price target by a few dollars to reflect updated revenue estimates and product forecasts, while still viewing current growth and leverage characteristics as broadly consistent with comparable companies in the sector. Analyst Commentary Recent Street updates around Harrow are mixed, with several bearish analysts trimming price targets after incorporating the latest Q4 information and revised product assumptions.Narrative-Update • Mar 03
HROW: Future Upside Will Rely On Cataract Franchise Execution
Analysts have nudged their price target for Harrow higher to reflect slightly stronger assumptions for revenue growth and profit margins, as well as a modestly lower future P/E. This results in a small upward adjustment in their implied valuation in dollar terms.Narrative-Update • Feb 17
HROW: Future Upside Will Depend On Market Share Execution And Margin Expansion
Analysts have trimmed their price target on Harrow to $90.32 from $91.76, citing updated assumptions around revenue growth, profit margins, and a slightly lower future P/E multiple. What's in the News Harrow reaffirmed its full-year 2025 revenue guidance, keeping the range at US$270 million to US$280 million (Corporate Guidance).Narrative-Update • Feb 03
HROW: Future Upside Will Depend On Coverage And Market Share Execution
Analysts have nudged their price targets on Harrow higher, with moves such as the shift to $66 at Ladenburg and $94 at Cantor Fitzgerald. These adjustments support a modest uptick in our fair value estimate to $91.76 as they incorporate updated Q3 results, Vevye revenue assumptions and refined profitability expectations.Narrative-Update • Jan 20
HROW: Future Upside Will Rely On Execution And Insurance Coverage
Narrative Update Analysts have nudged their targets higher on Harrow, with recent price objectives rising to $66 and $94. These changes reflect updated models after the latest quarterly results and revised Vevye revenue assumptions.Narrative-Update • Jan 06
HROW: Raised Outlook Will Rely On Execution And Insurance Coverage
Narrative Update on Harrow Analysts have lifted their consolidated price target on Harrow from about $76 to roughly $90, noting updated models after recent quarterly results and refined expectations for Vevye revenue and future P/E assumptions. Analyst Commentary Bullish analysts are resetting their expectations higher for Harrow, with recent research pointing to revised models after the latest quarterly update and a closer look at Vevye revenue assumptions and future P/E expectations.Narrative-Update • Dec 19
HROW: Expanded Ophthalmic Pipeline Is Expected To Drive Stronger Long Term Earnings Power
Analysts have raised our Harrow fair value estimate to $59 from $42, reflecting higher modeled revenue growth, improving margin expectations, and a wave of increased Street price targets following stronger quarterly results and an expanded product and biosimilar pipeline. Analyst Commentary Recent Street commentary on Harrow has been broadly constructive, with multiple firms lifting price targets in response to stronger quarterly results, expanding ophthalmic franchises, and a more visible biosimilar contribution.Narrative-Update • Dec 05
HROW: Expanding Ophthalmic Portfolio Will Drive Long-Term Revenue Mix Diversification
Analysts have raised their blended price targets for Harrow into a higher range, highlighted by recent increases to $66, $70, $74, and $94 per share. They cite a stronger long-term revenue and margin outlook supported by ophthalmic biosimilars, Vevye ramp expectations, and a more visible commercial roadmap.Narrative-Update • Nov 21
HROW: Expanding Ophthalmic Pipeline Will Drive Revenue Upside Beyond 2026
Analysts have raised their price target for Harrow from $68.18 to $70.63. They cite sustained confidence in the company's revenue growth potential and the strength of its commercial roadmap, despite slight adjustments in growth projections and profit margins.Narrative-Update • Nov 05
HROW: Expanding Ophthalmic Pipeline Will Drive Strong Revenue Momentum Through 2027
Analysts have raised their price targets for Harrow. The most recent consensus lifts expectations by up to $4 per share, citing confidence in the company's expanding pipeline and commercial strategy to deliver sustainable revenue and margin growth.Narrative-Update • Oct 22
Analysts Boost Harrow Price Targets Amid Strong Growth Prospects and Pipeline Optimism
Analysts have raised their average price target for Harrow, citing increased confidence in the company's commercial execution and long-term revenue growth potential. Recent updates reflect new targets up to $74, compared to previous levels between $42 and $70.Narrative-Update • Oct 08
Rising Specialty Ophthalmics And Biosimilars Will Open New Markets
Harrow's analyst price target has increased from $61.98 to $68.18. Analysts point to a stronger revenue growth outlook and heightened optimism regarding the company's commercial execution and product pipeline.Analyseartikel • Oct 03
Harrow, Inc. (NASDAQ:HROW) Looks Just Right With A 27% Price Jump
Despite an already strong run, Harrow, Inc. ( NASDAQ:HROW ) shares have been powering on, with a gain of 27% in the...Narrative-Update • Sep 24
Rising Specialty Ophthalmics And Biosimilars Will Open New Markets
Analysts have raised Harrow's price target to $61.98, reflecting optimism about upcoming biosimilar launches, a strengthening market position in eye care, and expectations for upside to current revenue guidance. Analyst Commentary Introduction of ophthalmic biosimilars Byooviz and Opuviz expected to materially contribute to revenue starting in 2026.Neues Narrative • May 05
VEVYE And TRIESENCE Programs Will Expand Prescription Access
Harrow is focusing on boosting sales and profitability through patient affordability programs, strategic supply chain improvements, and next-gen product developments.Seeking Alpha • Mar 29
Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)
Summary Harrow's stock is down 17% since my last analysis and "Sell" recommendation. Harrow's Q4 and FY24 results show significant revenue growth and improved net income, but the company faces complex reimbursement challenges and tough competition. Valuation models suggest Harrow is fairly valued if it achieves 20% revenue growth and 15% FCF margins, though these are lofty expectations. I upgrade Harrow to "Hold" due to its solid earnings and more reasonable valuation, but remain cautious about its complex business structure and high growth targets. Read the full article on Seeking AlphaSeeking Alpha • Mar 19
Harrow: A Name I Am Accumulating
Summary Harrow, Inc. shares fell over 50% post a weak 3Q24 report but rebounded on preliminary Q4 results, showing potential for a strong FY2025. The company’s key products, Iheezo and Vevye, show significant market potential, with Vevye’s gross sales nearing $200 million annually. Harrow’s balance sheet remains solid despite increased debt, and analysts maintain Buy ratings with price targets around $55-$57. The 50% share price decline offers a solid entry point, with promising preliminary Q4 numbers and FY2025 projections indicating future growth. An updated analysis around HROW stock follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Mar 01
Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025
Summary Harrow Health's robust distribution platform and patented eye care products create a strong moat, offering an attractive entry point after the recent stock price correction. Catalysts in 2025 could come from a successful Triesence launch and potential NDA filing for Melt pharma, where HROW has a material stake. The main risk is the company's loss in Q3 2024 despite recent acquisitions, so more revenue growth alongside controlled costs is needed for the stock to work from here. With good progress on Triesence and Melt's NDA filing, it's possible the stock could double to around $55/share in 2025. Nonetheless, without anticipated progress on these two major catalysts, the current $27/share valuation would be at risk. Read the full article on Seeking AlphaAnalyseartikel • Feb 17
Shareholders Should Be Pleased With Harrow, Inc.'s (NASDAQ:HROW) Price
Harrow, Inc.'s ( NASDAQ:HROW ) price-to-sales (or "P/S") ratio of 6.4x might make it look like a strong sell right now...Seeking Alpha • Dec 14
Harrow: The Triesence Relaunch
Summary Harrow's relaunch of Triesence, a preservative-free corticosteroid, addresses a critical unmet need in ophthalmology, offering safer and more effective treatment options for eye care professionals. Triesence's unique formulation and absence of preservatives make it superior to alternatives like Kenalog, despite its higher price point and previous supply chain issues. Harrow's acquisition and relaunch of Triesence, with 39,000 units available, positions the company for significant market growth, targeting over 500,000 units annually. Despite the price hike to $944 per vial, Harrow justifies it with increased regulatory and manufacturing costs, aiming for consistent and reliable supply. Read the full article on Seeking AlphaSeeking Alpha • Nov 16
Harrow: Spotlight On IHEEZO
Summary Harrow Inc.'s poor Q3 earnings were due to an inventory shortage for VEVYE and a strategic pivot with IHEEZO, but recovery is expected in Q4. VEVYE's strong refill rate of over 90% demonstrates its clinical value, despite the temporary inventory issues that capped its Q3 revenue potential. IHEEZO's demand growth slowed due to a strategic focus on retina specialists, but higher reimbursement and new agreements promise future benefits. Harrow's cash position remains strong, and strategic moves like the TRIESENCE milestone payment indicate long-term growth potential, making the current share price drop a buying opportunity. This is my second article in a series on Harrow's products. Read the full article on Seeking AlphaSeeking Alpha • Oct 02
Harrow's Focus - Reviving Old Drugs In A Crowded Market
Summary Harrow focuses on ophthalmology products, including Iheezo, Vevye, and Triesence, but its clinical differentiation is debatable. HROW reported a record $48.9 million in Q2 revenue, a 46% year-over-year increase, though net losses persist. The Company's current ratio is over 2, indicating strong short-term financial health, but significant debt due in 2026 could impact the cash runway. Harrow's products compete against established generics, and it heavily relies on marketing and sales force expansion to drive growth. The investment recommendation is a "sell," due to concerns over product differentiation, financial risks, and limited market advantage. Read the full article on Seeking AlphaSeeking Alpha • Sep 10
Harrow: 3 Business Models, One Mission
Summary Harrow's CEO, Mark Baum, transformed the company from a struggling OTC penny stock to a leader in ophthalmic compounding drugs, emphasizing accessible healthcare. Harrow's business model includes a core compounding pharmacy, an expanding portfolio of FDA-approved drugs, and a biotech incubator, minimizing regulatory risks. The company's branded product segment is experiencing significant growth, with notable drugs like IHEEZO and VEVYE targeting large market opportunities. Despite challenges, Harrow's management talent and strategic focus on de-risking commercial and regulatory processes position it for continued success. Read the full article on Seeking AlphaSeeking Alpha • Aug 21
Borrowing Cash To Burn It: The Curious Case Of Harrow
Summary Harrow reported a $20 million loss for the first half of 2024, doubling from the previous year. Increased competition from generics and new drugs will squash margins. Harrow's recent strategy shift has led to increased expenses and losses, with a potential stock price target of $4. Read the full article on Seeking AlphaSeeking Alpha • May 02
Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom
Summary Harrow's long-term bull thesis is stronger than ever, but there may be a credible short-term bear thesis. The short-term bear thesis is the result of the Change Healthcare cyberattack, which has crippled reimbursement and caused huge financial headaches for healthcare providers. Harrow will definitely miss Q1 2024 earnings estimates as a result. Although the cyberattack is widely known, sell side estimates have not been updated to reflect the impact. This needs to be weighed against the swath of good news Harrow is experiencing, with every development other than the cyberattack turning out better than expected. Read the full article on Seeking AlphaSeeking Alpha • Feb 19
Harrow's Drug Iheezo Is Off To A Great Start
Summary Harrow Inc. is leveraging its existing customer base in the compounded ophthalmic pharmaceutical products business to expand into branded pharmaceuticals. The company's first major branded drug, Iheezo, initially faced skepticism but has seen significant success, with December 2023 sales reaching an estimated $5 million, triple the November rate. The success of Iheezo suggests that Harrow's distribution platform and customer base can support the success of other branded drugs, potentially leading to a triple-digit share price. Read the full article on Seeking AlphaSeeking Alpha • Jan 30
Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity
Summary Harrow, Inc.'s stock price has fallen due to disappointing earnings releases in Q1, Q2, and Q3 of 2023. The company's various revenue buckets have not performed as well as expected, leading to a decline in revenue. Despite short-term challenges, Harrow has a long-term growth strategy. Read the full article on Seeking AlphaAktionärsrenditen
| HROW | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | 3.5% | 3.2% | 2.7% |
| 1Y | 19.9% | 57.6% | 20.9% |
Rendite im Vergleich zur Industrie: HROW unter dem Niveau der Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 57.6% erzielte.
Rendite vs. Markt: HROW entspricht dem US Markt, der im vergangenen Jahr eine Rendite von 20.9 erzielte.
Preisvolatilität
| HROW volatility | |
|---|---|
| HROW Average Weekly Movement | 9.8% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: HROW hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: HROWDie wöchentliche Volatilität (10%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1998 | 373 | Mark Baum | www.harrow.com |
Harrow, Inc. ist ein pharmazeutisches Unternehmen im Bereich der Augenheilkunde, das sich mit der Erforschung, Entwicklung und Vermarktung von pharmazeutischen Produkten für die Augenheilkunde in den Vereinigten Staaten beschäftigt. Das Unternehmen ist in den Segmenten Branded und ImprimisRx tätig. Das Unternehmen bietet ImprimisRx an, ein auf die Ophthalmologie ausgerichtetes Medikamentenpräparat.
Harrow, Inc.'s Grundlagenzusammenfassung
| HROW grundlegende Statistiken | |
|---|---|
| Marktanteil | US$1.51b |
| Gewinn(TTM) | -US$14.96m |
| Umsatz(TTM) | US$268.68m |
5.6x
Kurs-Umsatz-Verhältnis-100.8x
Kurs-Gewinn-Verhältnis Ist HROW zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| HROW Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$268.68m |
| Kosten der Einnahmen | US$69.57m |
| Bruttogewinn | US$199.11m |
| Sonstige Ausgaben | US$214.07m |
| Gewinn | -US$14.96m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
Aug 10, 2026
| Gewinn per Aktie (EPS) | -0.40 |
| Bruttomarge | 74.11% |
| Nettogewinnspanne | -5.57% |
| Schulden/Eigenkapital-Verhältnis | 1,030.3% |
Wie hat sich HROW auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/10 08:11 |
| Aktienkurs zum Tagesende | 2026/08/07 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Harrow, Inc. wird von 10 Analysten beobachtet. 8 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |
| Steven Seedhouse | Cantor Fitzgerald & Co. |